Navigation Links
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Date:10/18/2007

Top Line Results of Phase II Study in Previous Nonresponders also Reported

KENILWORTH, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today provided an update on the clinical development program for boceprevir, its investigational oral hepatitis C protease inhibitor. Initial results from an ongoing Phase II study in treatment-naive (previously untreated) hepatitis C patients showed boceprevir (800 mg TID) in combination with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) achieved a high rate of early virologic response, with up to 79 percent of patients having undetectable virus (HCV-RNA) at week 12 of boceprevir treatment compared to 34 percent of patients receiving PEGINTRON and REBETOL alone.

"These initial results, while preliminary, are very encouraging, and showed that boceprevir is a potent antiviral agent for hepatitis C," said Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, and the lead investigator of the study. "In this study, boceprevir improved viral clearance rates at week 12 in genotype 1 hepatitis C infection compared to the control group. We look forward to further results from this ongoing study."

Boceprevir is being evaluated in combination with PEGINTRON and REBETOL for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1 in two large Phase II clinical studies, in which more than 800 patients have received boceprevir. One study involves treatment-naive patients and the other involves patients who were nonresponders to previous peginter
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
5. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
6. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Sygnis Pharma AG announces date for presentation of clinical results
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
(Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 /PRNewswire/ ... that its shareholders have approved Mylan,s proposed acquisition ... TASE) and the related issuance of Mylan ordinary ... meeting of shareholders held today. The transaction received ... extraordinary general meeting. In addition, the transaction received ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... BETHESDA, Md., May 14 Spherix Incorporated (Nasdaq: SPEX ), ... and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today ... Company Highlights , , ... Created a wholly owned subsidiary, Biospherics Incorporated, ...
... SAN DIEGO, May 14 TargeGen, Inc. today ... a multi-center clinical trial of TG101348, an oral, ... patients with myelofibrosis on May 7, 2009.(Logo: ... conducted at six centers in the USA. The ...
Cached Medicine Technology:Spherix Reports First Quarter 2009 Earnings 2Spherix Reports First Quarter 2009 Earnings 3Spherix Reports First Quarter 2009 Earnings 4Spherix Reports First Quarter 2009 Earnings 5Spherix Reports First Quarter 2009 Earnings 6Spherix Reports First Quarter 2009 Earnings 7
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... to have beneficial effects as sleep aids and calming remedies, which help to improve ... the result of a great deal of research in the field of regenerative medicine ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Dr. Tim Novelli, ... His mission is to increase acceptance of the chiropractic field in the military. ... further debilitate them. Although Chiropractic was made available to the VA program over ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... checking the profits and safety of the drugs the ... monitor that only branded and quality medicines are sold ... Pharmaceutical Price Regulation Scheme [PPRS] is a voluntary organization ... and quality of the drugs every 5 years. It ...
... to bare metal stents, placement of stents that ... the artery re-narrowing nine months following angioplasty for ... an article in the September 14 issue of ... of atherosclerotic coronary artery disease, according to background ...
... up with a disaster-planning guide to help the people ... tropical storms, hurricanes, tidal waves and cyclones. ,No ... vulnerable to some sort of natural disaster such as ... terrorist attacks are also possible. Both natural disasters and ...
... findings of a recent study researchers say that certain chemicals ... to help current and former smokers ward off development of ... ,Researchers say their study provides significant insight into ... which the process can be slowed down after exposure has ...
... over the increasing malfunction of heart devices, which they ... and 2002. ,The Food and Drug Administration (FDA) ... and heart-device manufacturers recently, which found that 4,225 defibrillators ... defibrillators failed in the previous 10 years, reports online ...
... Mammography is used for early detection of breast cancer and ... year and self examination of the breasts for lumps every ... of cancer is necessary to start an early treatment which ... reported in the New England Journal of Medicine has shown ...
Cached Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Stents That Release Medication To Check Artery Narrowing 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2Health News:Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: